Free Notice to Take Deposition - District Court of Delaware - Delaware

Case 1:07-md-01866-GMS

Document 38

Filed 05/05/2008

Page 1 of 5

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

IN RE: BRIMONEDINE PATENT LITIGATION

C.A. 07-md-01866 GMS

NOTICE OF DEPOSITION OF DEFENDANT PADDOCK LABORATORIES, INC. PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 30(b)(6) PLEASE TAKE NOTICE that, pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, Plaintiff Allergan Inc. ("Plaintiff') by its counsel, will take the deposition of Defendant Paddock Laboratories, Inc. ("Defendant") at the offices of Fish & Richardson P.C., 919 N. Market Street, Suite 1100, Wilmington, Delaware 19899, commencing at 9:00 a.m. on May 29, 2008, or at such other place and time as may be agreed upon by counsel. The deposition will continue from day to day until completed. Some or all of the deposition testimony may be recorded by stenographic, audio, audiovisual, video, and/or real-time computer means. The subject matters of the deposition are enclosed herein. Pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, Defendant is obligated to designate one or more officers, directors, managing agents, or other persons who consent to testify on its behalf concerning the matters set forth in the attached Appendix. Plaintiff requests that Defendant provide, on or before May 21, 2008, a written designation of the names and positions of the officers, directors, or other persons who are most competent to testify concerning the topics set forth below, and for each person designated, the matters on which he or she will testify.

Case 1:07-md-01866-GMS

Document 38

Filed 05/05/2008

Page 2 of 5

DEFINITIONS The definitions set forth in Plaintiffs First Set of Interrogatories shall apply as if fully set forth herein. RULE 30(b)(6) TOPICS FOR DEPOSITION 1. 2. 3. lawsuit. 4. 5. 6. 7. 8. Defendant's role in the development of the proposed brimonidine product. The formulation of Defendant's proposed brimonidine product. The development of Defendant's proposed brimonidine product. The intended use of Defendant's proposed brimonidine product. All testing of Defendant's proposed brimonidine product, or any formulations Defendant's organizational structure. Defendant's corporate structure. Defendant's relationship to and interactions with the other defendants in this

employed in the development of Defendant ' s proposed brimonidine product , or any components of Defendant' s proposed brimonidine product. 9. 10. Defendant's ANDA No. 78-590. Defendant' s interactions with the FDA regarding Defendant's proposed

brimonidine product , ANDA No. 78-590 and/or Allergan 's ALPHAGAN 0.15% product, including all communications with the FDA regarding ANDA No. 78-590 and/or Allergan's ALPHAGAN P 0.15% product. 11. product. 12. Any Bioequivalence and/or bioavialibity Testing for ANDA No. 78-590 or Any Clinical Trials for ANDA No. 78-590 or defendant's proposed brimonidine

defendant's proposed brimonidine product.

2

Case 1:07-md-01866-GMS

Document 38

Filed 05/05/2008

Page 3 of 5

13.

The alleged therapeutic equivalence of defendant's proposed brimonidine product

to Allergan 's ALPHAGAN P 0.15%. 14. Each ingredient in Defendant ' s proposed brimonidine product, its function(s) in

the formulation and the reasons (s) why such ingredient included in the formulation. 15. 16. All testing of Allergan 's ALPHAGAN products. The differences between Defendant ' s proposed brimonidine product and

Allergan's ALPHAGAN P .15%. 17. 18. 19. 20. 21. When Defendant became aware of U.S . Patent No . 6,641,834 ("the '834 patent"). Defendant's knowledge of the '834 patent. Defendant's experience with and/or knowledge of the ophthalmic industry. Defendant ' s business reasons for developing and filing ANDA No. 78-590. Defendant ' s interactions with doctors and/or healthcare professionals with regard

to the proposed brimonidine product or potential brimonidine based ophthalmic products.

3

Case 1:07-md-01866-GMS

Document 38

Filed 05/05/2008

Page 4 of 5

Dated: May 5, 2008

FISH & RICHARDSON P.C.

By: k Wi4liar'n J. arsd n, Jr. (#2247) san M. Coletti (#4690) 919 N. Market Street, Suite 1100 P.O. Box 1114 Wilmington, DE 19899-1114 Telephone: (302) 652-5070 Email: [email protected] Of Counsel: Jonathan E. Singer Michael J. Kane Deanna J. Reichel FISH & RICHARDSON P.C. 60 South Sixth Street, Suite 3300 Minneapolis, MN 55402 Telephone: (612) 335-5070 Juanita Brooks FISH & RICHARDSON P.C. 12390 El Camino Real San Diego, CA 92130 Telephone: (858) 678-5070 W. Chad Shear FISH & RICHARDSON P.C. 1717 Main St., Suite 5000 Dallas, TX 75201 Telephone : (214) 747-5070
ATTORNEYS FOR PLAINTIFF ALLERGAN, INC.

60491670.doc

4

Case 1:07-md-01866-GMS

Document 38

Filed 05/05/2008

Page 5 of 5

CERTIFICATE OF SERVICE I hereby certify that on May 5, 2008, I electronically filed with the Clerk of Court the NOTICE OF DEPOSITION OF DEFENDANT PADDOCK LABORATORIES, INC. PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 30(b)(6) using CM/ECF which will send electronic notification of such filing (s) to the following counsel.

VIA EMAIL AND FEDERAL EXPRESS Walter J. Kawula Sherry Rollo Welsh & Katz, Ltd. 120 South Riverside Plaza, 22nd Floor Chicago, IL 60606 VIA EMAIL AND HAND DELIVERY Frederick L. Cottrell, III Kelly E. Farnan Richard, Layton & Finger One Rodney Square Wilmington, DE 19899

VIA EMAIL AND HAND DELIVERY Richard L. Horwitz Potter Anderson & Corroon LLP Hercules Plaza 1313 North Market Street, 6th Floor Wilmington, DE 19899 VIA EMAIL AND FEDERAL EXPRESS Daniel G. Brown Arthur L. Hoag David A. Zwally Brian J. Malkin Omar Jabri Frommer Lawrence & Haug LLP 745 Fifth Avenue New York, NY 10151 VIA EMAIL AND FEDERAL EXPRESS Robert B. Breisblatt Jeremy C. Daniel Joanna R. Stevason Katten Muchin Rosenmann LLP 525 West Monroe Street Chicago, IL 60601-3693

VIA EMAIL AND FEDERAL EXPRESS Roderick G. Dorman Hennigan, Bennett & Dorman LLP 865 South Figueroa Street , Suite 2900 Los Angeles , CA 90017

5